Bank Of America Corp Novo Cure LTD Call Options Transaction History

Bank Of America Corp

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$15.61 - $23.34 $1.17 Million - $1.75 Million	-75,000 Reduced 62.45%	45,100 $704,000
Q1 2024 May 15, 2024	SELL	$12.42 - $17.29 $972,486 - $1.35 Million	-78,300 Reduced 39.47%	120,100 $1.88 Million
Q4 2023 Feb 14, 2024	BUY	$11.13 - $15.78 $1.74 Million - $2.47 Million	156,300 Added 371.26%	198,400 $2.96 Million
Q2 2023 Aug 14, 2023	SELL	$40.29 - $82.51 $2.33 Million - $4.78 Million	-57,900 Reduced 57.9%	42,100 $1.75 Million
Q1 2023 May 12, 2023	BUY	$56.44 - $118.81 $3.39 Million - $7.13 Million	60,000 Added 150.0%	100,000 $6.01 Million
Q4 2021 Feb 08, 2022	SELL	$75.08 - $121.99 $1.82 Million - $2.96 Million	-24,300 Reduced 37.79%	40,000 $3 Million
Q2 2021 Sep 13, 2021	BUY	$130.4 - $225.58 $8.38 Million - $14.5 Million	64,300 New	64,300 $14.3 Million

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.25B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.